Floatz logo

Cyclophosphamide

Metastatic Gastric Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

49 Active assets in the Metastatic Gastric Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 1/2CCC
Fexagratinib
National Cancer Institute (NCI)
Phase 2CCC
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →